Mark R. Denison

{{Short description|Pediatrician}}

{{Multiple issues|

{{orphan|date=January 2022}}

{{BLP primary sources|date=January 2022}}

}}

Mark R. Denison (born May 13, 1955){{cite web|title=Mark R. Denison|website=United States Public Records (via familysearch.org)|url=https://www.familysearch.org/ark:/61903/1:1:QJ7X-QQD9}} is the Stahlman Professor of Pediatrics, Pathology, Microbiology & Immunology and director of the Division of Pediatric Infectious Diseases at Vanderbilt University Medical Center. Denison has been researching the replication, pathogenesis and evolution of coronaviruses for over 30 years, and has published his research on SARS-CoV, MERS-CoV, and the current SARS-CoV-2.{{Cite web|url=https://www.vumc.org/global-health/person/mark-denison-md|title=Mark Denison, MD | Vanderbilt Institute for Global Health|website=www.vumc.org}}

Education and career

Denison obtained a B.A. in Chemistry and English in 1977 from the University of Kansas and an M.D. in 1980 from the University of Kansas School of Medicine.{{cite web|title=Mark R. Denison|website=ORCID (Open Researcher and Contributor ID)|url=https://orcid.org/0000-0003-2655-0900}}

Denison led the team that developed the remdesivir drug to treat COVID-19.{{cite news |title=Coronavirus - How to beat the next pandemic |url=https://www.theaustralian.com.au/weekend-australian-magazine/coronavirus-how-to-beat-the-next-pandemic/news-story/77989c4bfcb4fc7a120533e159dd35ff |access-date=19 March 2022}}

In 2011 he was elected a Fellow of the American Association for the Advancement of Science.{{cite web|title=Historic Fellows|website=American Association for the Advancement of Science|url=https://www.aaas.org/fellows/historic}}

References

{{reflist}}